Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy.

Annals of surgical oncology - 1 Apr 2010

Siddiqui Ahmad D, Piperdi Bilal

Abstract excerpt

INTRODUCTION AND DESIGN: The introduction of the epidermal growth factor receptor inhibitors (EGFR-I) has increased the treatment options available for patients with metastatic colorectal cancer (mCRC). Two EGFR-I agents currently approved for the treatment of mCRC are the fully human monoclonal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Clinical Trials as Topic
Share to Colonic Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 19936839
DOI: 10.1245/s10434-009-0811-z
PMCID: PMC2840670

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19936839-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy.PMID 19936839Read ↗

Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancerSemantic proximity Read ↗

An overview of KRAS-targeting therapies for colorectal cancer in phase I and II development.Semantic proximity Read ↗

KRAS testing and its importance in colorectal cancer.Semantic proximity Read ↗

KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer.Semantic proximity Read ↗

KRAS Mutations and Susceptibility to Cetuximab and Panitumumab in Colorectal CancerSemantic proximity Read ↗

KRAS mutation testing in colorectal cancer.Semantic proximity Read ↗

KRAS: A Druggable Target in Colon Cancer Patients.Semantic proximity Read ↗

Panitumumab in the treatment of colon cancer: A biomarker dilemma.Semantic proximity Read ↗

KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.Semantic proximity Read ↗

Prognostic and Predictive Roles of KRAS Mutation in Colorectal CancerSemantic proximity Read ↗

Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.Semantic proximity Read ↗

Personalized cancer treatment and the myth of KRAS wild-type colon tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.